BIOTTS is a Polish biotechnological company that develops proprietary drug delivery technologies and drug formulas in the field of oncology, dermatology, and autoimmune diseases. The team of Biotts technologists has developed a proprietary technology for obtaining a universal transdermal therapeutic system: MTC-Y. Thanks to the unique properties of the system, it is possible to increase the bioavailability of active substances by several times, allowing active substances to penetrate through skin barriers up to several centimetres, reaching soft tissues and bones. The unique transdermal MTC-Y system can be easily modified to achieve a targeted action in pathologically changed tissues. By increasing the bioavailability of the substance, it is possible to reduce the therapeutic dose, while maintaining the original effect and, at the same time, reducing the side effects. The unique transdermal Biotts system enables the transport of one to several active substances, thanks to which it is possible to design multi-component drugs.